TY - JOUR
T1 - First trimester insulin resistance and subsequent preeclampsia
T2 - A prospective study
AU - Wolf, Myles
AU - Sandler, Laura
AU - Muñoz, Kristine
AU - Hsu, Karen
AU - Ecker, Jeffrey L.
AU - Thadhani, Ravi
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Insulin resistance is implicated in the pathogenesis of preeclampsia, but prospective data are limited. SHBG, a marker of insulin resistance among nonpregnant individuals, has not been studied in detail during pregnancy. We conducted a prospective, nested, case-control study to test the hypothesis that increased insulin resistance, marked by reduced first trimester SHBG levels, is associated with increased risk of subsequent preeclampsia. First trimester SHBG levels were measured in 45 nulliparous women who subsequently developed preeclampsia (blood pressure, ≥140/90 mm Hg; proteinuria, either ≥2 + by dipstick or ≥300 mg/24 h, after 20 wk gestation) and in 90 randomly selected normotensive nulliparous controis. Compared with controls, women who developed preeclampsia had significantly reduced first trimester SHBG levels (302 ± 130 vs. 396 ± 186 nmol/liter; P < 0.01). Every 100 nmol/liter increase in SHBG was associated with a 31% reduced risk of preeclampsia [odds ratio (OR), 0.69; 95% confidence interval (CI), 0.55, 0.88; P < 0.01]. After adjusting for covariates in a multiple logistic regression model, the association between first trimester SHBG and preeclampsia remained significant (per 100 nmol/liter increase; OR, 0.66; 95% CI, 0.47, 0.92; P = 0.01). When subjects were stratified by body mass index (lean: body mass index, < 25 kg/m2; overweight: body mass index, ≥25 kg/m2), overweight women had lower SHBG levels than lean women (286 ± 156 vs. 410 ± 166 nmol/ liter; P < 0.01), and within each stratum, women with preeclampsia had lower SHBG levels than their respective controls. In a multivariable analysis, the association between SHBG and preeclampsia strengthened among lean women, such that every 100 nmol/liter increase in serum SHBG was associated with a 55% reduction in the risk of preeclampsia (OR, 0.45; 95% CI, 0.27, 0.77; P < 0.01), whereas in overweight women, the association was mitigated (OR, 1.02; 95% CI, 0.62, 1.69; P = 0.9). We conclude that increased early pregnancy insulin resistance is independently associated with subsequent preeclampsia. First trimester SHBG levels may be a useful biomarker for preeclampsia, especially among lean women who otherwise would be perceived to be at low risk.
AB - Insulin resistance is implicated in the pathogenesis of preeclampsia, but prospective data are limited. SHBG, a marker of insulin resistance among nonpregnant individuals, has not been studied in detail during pregnancy. We conducted a prospective, nested, case-control study to test the hypothesis that increased insulin resistance, marked by reduced first trimester SHBG levels, is associated with increased risk of subsequent preeclampsia. First trimester SHBG levels were measured in 45 nulliparous women who subsequently developed preeclampsia (blood pressure, ≥140/90 mm Hg; proteinuria, either ≥2 + by dipstick or ≥300 mg/24 h, after 20 wk gestation) and in 90 randomly selected normotensive nulliparous controis. Compared with controls, women who developed preeclampsia had significantly reduced first trimester SHBG levels (302 ± 130 vs. 396 ± 186 nmol/liter; P < 0.01). Every 100 nmol/liter increase in SHBG was associated with a 31% reduced risk of preeclampsia [odds ratio (OR), 0.69; 95% confidence interval (CI), 0.55, 0.88; P < 0.01]. After adjusting for covariates in a multiple logistic regression model, the association between first trimester SHBG and preeclampsia remained significant (per 100 nmol/liter increase; OR, 0.66; 95% CI, 0.47, 0.92; P = 0.01). When subjects were stratified by body mass index (lean: body mass index, < 25 kg/m2; overweight: body mass index, ≥25 kg/m2), overweight women had lower SHBG levels than lean women (286 ± 156 vs. 410 ± 166 nmol/ liter; P < 0.01), and within each stratum, women with preeclampsia had lower SHBG levels than their respective controls. In a multivariable analysis, the association between SHBG and preeclampsia strengthened among lean women, such that every 100 nmol/liter increase in serum SHBG was associated with a 55% reduction in the risk of preeclampsia (OR, 0.45; 95% CI, 0.27, 0.77; P < 0.01), whereas in overweight women, the association was mitigated (OR, 1.02; 95% CI, 0.62, 1.69; P = 0.9). We conclude that increased early pregnancy insulin resistance is independently associated with subsequent preeclampsia. First trimester SHBG levels may be a useful biomarker for preeclampsia, especially among lean women who otherwise would be perceived to be at low risk.
UR - http://www.scopus.com/inward/record.url?scp=0036277720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036277720&partnerID=8YFLogxK
U2 - 10.1210/jcem.87.4.8405
DO - 10.1210/jcem.87.4.8405
M3 - Article
C2 - 11932283
AN - SCOPUS:0036277720
VL - 87
SP - 1563
EP - 1568
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 4
ER -